- Home
- CBAN vs DMAC Comparison
CBAN vs DMAC Comparison
Compare CBAN & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBAN
- DMAC
- Stock Information
- Founded
- CBAN 1975
- DMAC 2000
- Country
- CBAN United States
- DMAC United States
- Employees
- CBAN N/A
- DMAC N/A
- Industry
- CBAN Major Banks
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- CBAN Finance
- DMAC Health Care
- Exchange
- CBAN Nasdaq
- DMAC Nasdaq
- Market Cap
- CBAN 287.3M
- DMAC 178.0M
- IPO Year
- CBAN 1998
- DMAC N/A
- Fundamental
- Price
- CBAN $17.44
- DMAC $3.76
- Analyst Decision
- CBAN
- DMAC Strong Buy
- Analyst Count
- CBAN 0
- DMAC 2
- Target Price
- CBAN N/A
- DMAC $8.00
- AVG Volume (30 Days)
- CBAN 52.3K
- DMAC 307.4K
- Earning Date
- CBAN 07-23-2025
- DMAC 08-06-2025
- Dividend Yield
- CBAN 2.64%
- DMAC N/A
- EPS Growth
- CBAN 14.66
- DMAC N/A
- EPS
- CBAN 1.43
- DMAC N/A
- Revenue
- CBAN $113,756,000.00
- DMAC N/A
- Revenue This Year
- CBAN $18.25
- DMAC N/A
- Revenue Next Year
- CBAN $7.59
- DMAC N/A
- P/E Ratio
- CBAN $12.17
- DMAC N/A
- Revenue Growth
- CBAN 3.33
- DMAC N/A
- 52 Week Low
- CBAN $11.93
- DMAC $2.80
- 52 Week High
- CBAN $18.49
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- CBAN 71.33
- DMAC 47.18
- Support Level
- CBAN $16.45
- DMAC $3.48
- Resistance Level
- CBAN $17.38
- DMAC $3.99
- Average True Range (ATR)
- CBAN 0.40
- DMAC 0.32
- MACD
- CBAN 0.20
- DMAC -0.00
- Stochastic Oscillator
- CBAN 98.39
- DMAC 41.01
About CBAN Colony Bankcorp Inc.
Colony Bankcorp Inc is a bank holding company. The bank provides a broad range of banking services to its retail and commercial customers. Its product line includes loans to small and medium-sized businesses, residential and commercial construction and land development loans, commercial real estate loans, agri-business and production loans, residential mortgage loans, consumer loans, and a variety of demand, savings, and time deposit products. The company's segments include the Banking Division, Retail Mortgage Division and small business specialty lending divisions. It generates maximum revenue from the Banking Division.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.